Abstract
Background
Galectin-3 (Gal-3) is a β-galactoside-binding lectin involved in regulating cell growth, angiogenesis, and tumor progression. We investigated the clinical significance of Gal-3 expression including its possible use as a prognostic marker or therapeutic target in epithelial ovarian carcinoma (EOC).
Methods
Gal-3 expression was evaluated by immunohistochemistry in 71 patients with 54 serous, 13 endometrioid, and 4 mucinous ovarian carcinomas. We assessed the correlation of Gal-3 expression with clinical characteristics including histology, optimal debulking, chemosensitivity, and survival. In vitro, Gal-3 was inhibited using siRNA to evaluate its role in cell growth and sensitivity to chemotherapeutic agents in ovarian carcinoma cell lines.
Results
Gal-3 protein, which was mainly cytoplasmic in location, was observed in a majority (63/71, 88.7%) of the EOCs but not in normal ovarian tissues (P < 0.001). High Gal-3 expression in EOCs correlated with shorter progression-free survival (PFS) of patients (P = 0.039; 43.1 and 49.5 months, respectively). Moreover, cotreatment with Gal-3 siRNA and paclitaxel showed an enhanced cytotoxic effect compared with control siRNA in SKOV3 cells.
Conclusion
These findings suggest that Gal-3 expression can be a prognostic factor for PFS and may be involved in regulating the response to paclitaxel-based chemotherapy in the treatment of EOC.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130
Kim K, Ryu SY (2009) Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol 20:198
Banerjee S, Gore M (2009) The future of targeted therapies in ovarian cancer. Oncologist 14:706–716
Barondes SH, Cooper DN, Gitt MA et al (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807–20810
Hirabayashi J, Kasai K (1993) The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology 3:297–304
Elola MT, Wolfenstein-Todel C, Troncoso MF et al (2007) Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 64:1679–1700
Le Mercier M, Fortin S, Mathieu V et al (2010) Galectins and gliomas. Brain Pathol 20:17–27
Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17
Davidson PJ, Li SY, Lohse AG et al (2006) Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import. Glycobiology 16:602–611
Ochieng J, Furtak V, Lukyanov P (2004) Extracellular functions of galectin-3. Glycoconj J 19:527–535
Matarrese P, Fusco O, Tinari N et al (2000) Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85:545–554
Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93:6737–6742
Akahani S, Nangia-Makker P, Inohara H et al (1997) Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57:5272–5276
Bresalier RS, Mazurek N, Sternberg LR et al (1998) Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 115:287–296
van den Brule F, Califice S, Castronovo V (2004) Expression of galectins in cancer: a critical review. Glycoconj J 19:537–542
van den Brule FA, Berchuck A, Bast RC et al (1994) Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 30A:1096–1099
Brustmann H (2008) Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol 27:380–389
Oishi T, Itamochi H, Kigawa J et al (2007) Galectin-3 may contribute to cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 17:1040–1046
Saussez S, Decaestecker C, Mahillon V et al (2008) Galectin-3 upregulation during tumor progression in head and neck cancer. Laryngoscope 118:1583–1590
Lee JW, Lee SJ, Seo J et al (2005) Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecol Oncol 97:53–59
Shimonishi T, Miyazaki K, Kono N et al (2001) Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32:302–310
Nakahara S, Raz A (2008) Biological modulation by lectins and their ligands in tumor progression and metastasis. Anticancer Agents Med Chem 8:22–36
Nangia-Makker P, Hogan V, Honjo Y et al (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94:1854–1862
Bresalier RS, Yan PS, Byrd JC et al (1997) Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer (Phila) 80:776–787
Schoeppner HL, Raz A, Ho SB et al (1995) Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer (Phila) 75:2818–2826
Miyazaki J, Hokari R, Kato S et al (2002) Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 9:1307–1312
Davidson PJ, Davis MJ, Patterson RJ et al (2002) Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12:329–337
Takenaka Y, Fukumori T, Raz A (2004) Galectin-3 and metastasis. Glycoconj J 19:543–549
Balasubramanian K, Vasudevamurthy R, Venkateshaiah SU et al (2009) Galectin-3 in urine of cancer patients: stage and tissue specificity. J Cancer Res Clin Oncol 135:355–363
Lin CI, Whang EE, Abramson MA et al (2009) Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 379:626–631
Guess BW, Scholz MC, Strum SB et al (2003) Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis 6:301–304
Takei Y, Kadomatsu K, Yuzawa Y et al (2004) A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64:3365–3370
Hingorani SR, Jacobetz MA, Robertson GP et al (2003) Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 63:5198–5202
Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243–247
Glinsky VV, Kiriakova G, Glinskii OV et al (2009) Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia 11:901–909
Acknowledgments
This study was supported by a grant from the Korea Health 21 R&D Project of the Ministry of Health & Welfare, Republic of Korea (A090088).
Conflict of interest
No author has any conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Additional information
M. K. Kim and C. O. Sung contributed equally to this paper.
This abstract was chosen as a poster presentation at 2010 IGCS (International Gynecologic Cancer Society) (A-214-0003-01288).
About this article
Cite this article
Kim, M.K., Sung, C.O., Do, IG. et al. Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol 16, 352–358 (2011). https://doi.org/10.1007/s10147-011-0190-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-011-0190-x